Research map: Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice

Back to the article

Papers in this map

  1. Transthyretin Amyloid Cardiomyopathy · Frederick L. Ruberg · 2019 · 1123 citations · Cited by this paper
  2. Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context · 2025 · Related
  3. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician · Lawrence Blonde · 2018 · 739 citations · Cited by this paper
  4. Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in Japan: A Claims Database Study · 2025 · Related
  5. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis · Thirusha Lane · 2019 · 543 citations · Cited by this paper
  6. A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit · 2026 · Related
  7. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy · Julian David Gillmore · 2024 · 535 citations · Cited by this paper
  8. Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies · 2024 · Related
  9. Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making · Marc L. Berger · 2017 · 357 citations · Cited by this paper
  10. Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy · 2025 · Related
  11. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years · Adam Ioannou · 2022 · 249 citations · Cited by this paper
  12. Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy · 2025 · Related
  13. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis · Mark Miller · 2018 · 111 citations · Cited by this paper
  14. Cardiogenic Shock Centers and Protocols for Acute Cardiovascular Care: Bridging the Gap Between Spoke and Hub Sites · 2026 · Related
  15. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine · Esther González-López · 2024 · 59 citations · Cited by this paper
  16. Resistant Blood Pressure: New Frontiers in Interventional Hypertension Therapy · 2025 · Related
  17. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy · Daniel Philip Judge · 2025 · 57 citations · Cited by this paper
  18. Patient Experience of Heart Disease with Elevated Lipoprotein(a): Views from a Patient, His Physician, and a Patient Association · 2025 · Related
  19. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS) · Pablo García‐Pavía · 2024 · 54 citations · Cited by this paper
  20. Transthyretin amyloid cardiomyopathy: from cause to novel treatments · Marianna Fontana · 2025 · 37 citations · Cited by this paper
  21. A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy · Ahmad Masri · 2025 · 32 citations · Cited by this paper
  22. Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options · Carsten Tschöpe · 2025 · 22 citations · Cited by this paper
  23. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM · Ahmad Masri · 2025 · 12 citations · Cited by this paper
  24. Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care · Julian David Gillmore · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)